| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 遺伝子 | 疾患 | 遺伝形式 | 対象人口 | 保因者頻度 | 検出率 | 検査後保因確率 | 残存リスク | ||||||||||||||||||
2 | ABCA12 | Congenital ichthyosis, ABCA12-related | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
3 | ABCA3 | Surfactant metabolism dysfunction, pulmonary 3 | AR | General Population | 1 in 116 | 99% | 1 in 11,501 | 1 in 5,336,464 | ||||||||||||||||||
4 | ABCA4 | Stargardt disease | AR | General Population | 1 in 51 | 98% | 1 in 2,501 | 1 in 510,204 | ||||||||||||||||||
5 | ABCB11 | Progressive familial intrahepatic cholestasis | AR | General Population | 1 in 112 | 98% | 1 in 5,551 | 1 in 2,486,848 | ||||||||||||||||||
6 | ABCB4 | Progressive familial intrahepatic cholestasis | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
7 | ABCC8 | Familial hyperinsulinism | AR | General Population | 1 in 112 | 98% | 1 in 5,551 | 1 in 2,486,848 | ||||||||||||||||||
8 | Ashkenazi Jewish Population | 1 in 44 | 98% | 1 in 2,151 | 1 in 378,576 | |||||||||||||||||||||
9 | Finnish Population | 1 in 25 | 98% | 1 in 1,201 | 1 in 120,100 | |||||||||||||||||||||
10 | Middle-Eastern Population | 1 in 25 | 98% | 1 in 1,201 | 1 in 120,100 | |||||||||||||||||||||
11 | ABCD1 | Adrenoleukodystrophy, X-linked | XL | General Population | 1 in 21,000 | 99% | 1 in 2,099,901 | 1 in 8,399,804 | ||||||||||||||||||
12 | ABCD4 | Methylmalonic aciduria and homocystinuria, cblJ type | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
13 | ACAD9 | Acyl-CoA dehydrogenase-9 (ACAD9) deficiency | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
14 | ACADM | Medium-chain acyl-CoA dehydrogenase | AR | General Population | 1 in 69 | 98% | 1 in 3,401 | 1 in 938,676 | ||||||||||||||||||
15 | (MCAD) deficiency | Caucasian / European Population | 1 in 52 | 99% | 1 in 5,101 | 1 in 1,061,008 | ||||||||||||||||||||
16 | East Asian Population | 1 in 198 | 99% | 1 in 19,701 | <1 in 10 million | |||||||||||||||||||||
17 | Native American Population | 1 in 43 | 96% | 1 in 1,051 | 1 in 180,772 | |||||||||||||||||||||
18 | ACADS | Short-chain acyl-coA dehydrogenase (SCAD) | AR | General Population | 1 in 85 | 99% | 1 in 8,401 | 1 in 2,856,340 | ||||||||||||||||||
19 | deficiency | African/African American Population | 1 in 52 | 99% | 1 in 5,101 | 1 in 1,061,008 | ||||||||||||||||||||
20 | Caucasian / European Population | 1 in 76 | 99% | 1 in 7,501 | 1 in 2,280,304 | |||||||||||||||||||||
21 | Middle-Eastern Population | 1 in 52 | 99% | 1 in 5,101 | 1 in 1,061,008 | |||||||||||||||||||||
22 | South Asian/Indian Population | 1 in 51 | 99% | 1 in 5,001 | 1 in 1,020,204 | |||||||||||||||||||||
23 | ACADSB | Short branched chain acyl-CoA | AR | General Population | 1 in 368 | 99% | 1 in 36,701 | <1 in 10 million | ||||||||||||||||||
24 | dehydrogenase (SBCAD) deficiency | Hmong Population | 1 in 6 | 99% | 1 in 501 | <1 in 10 million | ||||||||||||||||||||
25 | ACADVL | Very long-chain acyl-CoA dehydrogenase | AR | General Population | 1 in 118 | 93% | 1 in 1,672 | 1 in 789,184 | ||||||||||||||||||
26 | (VLCAD) deficiency | Middle-Eastern Population | 1 in 74 | 93% | 1 in 1,044 | 1 in 309,024 | ||||||||||||||||||||
27 | Native American Population | 1 in 61 | 93% | 1 in 858 | 1 in 209,352 | |||||||||||||||||||||
28 | South Asian/Indian Population | 1 in 73 | 93% | 1 in 1,030 | 1 in 300,760 | |||||||||||||||||||||
29 | ACAT1 | 3-ketothiolase deficiency | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
30 | ACOX1 | Peroxisomal acyl-CoA oxidase deficiency | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
31 | ACSF3 | Combined malonic and methylmalonic aciduria | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
32 | ADA | Adenosine deaminase deficiency | AR | General Population | 1 in 224 | 93% | 1 in 3,187 | 1 in 2,855,552 | ||||||||||||||||||
33 | ADAMTS2 | Ehlers-Danlos syndrome, dermatosparaxis | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
34 | type | Ashkenazi Jewish Population | 1 in 248 | 98% | 1 in 12,351 | <1 in 10 million | ||||||||||||||||||||
35 | ADGRG1 | Bilateral frontoparietal polymicrogyria | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
36 | ADGRV1 | Usher syndrome, type IIC | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
37 | ADK | Hypermethioninemia due to adenosine kinase deficiency | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
38 | AFF2 | Fragile XE syndrome | XL | General Population | <1 in 50,000 | 98% | 1 in 2,499,951 | 1 in 9,999,804 | ||||||||||||||||||
39 | AGA | Aspartylglucosaminuria | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
40 | Finnish Population | 1 in 71 | 98% | 1 in 3,501 | 1 in 994,284 | |||||||||||||||||||||
41 | AGL | Glycogen storage disease type III | AR | General Population | 1 in 158 | 95% | 1 in 3,141 | 1 in 1,985,112 | ||||||||||||||||||
42 | Faroese Population | 1 in 28 | 95% | 1 in 541 | 1 in 60,592 | |||||||||||||||||||||
43 | Inuit Population | 1 in 25 | 95% | 1 in 481 | 1 in 48,100 | |||||||||||||||||||||
44 | North African Jewish Population | 1 in 37 | 95% | 1 in 721 | 1 in 106,708 | |||||||||||||||||||||
45 | AGPAT2 | Congenital generalized lipodystrophy, type 1 | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
46 | AGPS | Rhizomelic chondrodysplasia punctata, type 3 | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
47 | AGXT | Primary hyperoxaluria type 1 | AR | General Population | 1 in 120 | 99% | 1 in 11,901 | 1 in 5,712,480 | ||||||||||||||||||
48 | Caucasian / European Population | 1 in 173 | 99% | 1 in 17,201 | <1 in 10 million | |||||||||||||||||||||
49 | AHCY | Hypermethioninemia due to deficiency of S- adenosylhomocysteine hydrolase | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
50 | AHI1 | Joubert syndrome, AHI1-related | AR | General Population | 1 in 448 | 99% | 1 in 44,701 | <1 in 10 million | ||||||||||||||||||
51 | AIMP1 | Hypomyelinating leukodystrophy 3 | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
52 | AIPL1 | Childhood-onset severe retinal dystrophy, AIPL1-related | AR | General Population | 1 in 409 | 99% | 1 in 40,801 | <1 in 10 million | ||||||||||||||||||
53 | AIRE | Autoimmune polyendocrinopathy syndrome | AR | General Population | 1 in 150 | 98% | 1 in 7,451 | 1 in 4,470,600 | ||||||||||||||||||
54 | type I | Finnish Population | 1 in 79 | 98% | 1 in 3,901 | 1 in 1,232,716 | ||||||||||||||||||||
55 | AK2 | Reticular dysgenesis | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
56 | AKR1D1 | Congenital Bile Acid Synthesis Defect | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
57 | ALDH3A2 | Sjögren-Larsson syndrome | AR | General Population | 1 in 250 | 98% | 1 in 12,451 | <1 in 10 million | ||||||||||||||||||
58 | ALDH4A1 | Hyperprolinemia type II | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
59 | ALDH7A1 | Pyridoxine-dependent epilepsy | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
60 | ALDOB | Hereditary fructose intolerance | AR | General Population | 1 in 122 | 99% | 1 in 12,101 | 1 in 5,905,288 | ||||||||||||||||||
61 | African/African American Population | 1 in 250 | 99% | 1 in 24,901 | <1 in 10 million | |||||||||||||||||||||
62 | Caucasian / European Population | 1 in 67 | 99% | 1 in 6,601 | 1 in 1,769,068 | |||||||||||||||||||||
63 | Middle-Eastern Population | 1 in 97 | 99% | 1 in 9,601 | 1 in 3,725,188 | |||||||||||||||||||||
64 | ALG6 | Congenital disorder of glycosylation type Ic | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
65 | ALMS1 | Alstrom syndrome | AR | General Population | 1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
66 | ALOX12B | Autosomal recessive, congenital, ichthyosis 2 | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
67 | ALOXE3 | Congenital ichthyosiform erythroderma | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
68 | ALPL | Hypophosphatasia | AR | General Population | 1 in 158 | 95% | 1 in 3,141 | 1 in 1,985,112 | ||||||||||||||||||
69 | Caucasian / European Population | 1 in 274 | 95% | 1 in 5,461 | 1 in 5,985,256 | |||||||||||||||||||||
70 | Mennonite Population | 1 in 25 | 95% | 1 in 481 | 1 in 48,100 | |||||||||||||||||||||
71 | AMH | Persistent mullerian duct syndrome, type I | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
72 | AMHR2 | Persistent mullerian duct syndrome, type II | AR | General Population | <1 in 500 | 98% | 1 in 24,951 | <1 in 10 million | ||||||||||||||||||
73 | AMN | Megaloblastic anemia 1 | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
74 | AMPD2 | Pontocerebellar hypoplasia type 9 | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
75 | AMT | Glycine encephalopathy | AR | General Population | 1 in 373 | 98% | 1 in 18,601 | <1 in 10 million | ||||||||||||||||||
76 | Finnish Population | 1 in 117 | 98% | 1 in 5,801 | 1 in 2,714,868 | |||||||||||||||||||||
77 | ANO10 | Spinocerebellar ataxia 10 | AR | General Population | 1 in 93 | 99% | 1 in 9,201 | 1 in 3,422,772 | ||||||||||||||||||
78 | ANO5 | Gnathodiaphyseal dysplasia | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
79 | ANTXR2 | Hyaline fibromatosis syndrome | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
80 | AP1S1 | MEDNIK syndrome | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
81 | AP1S2 | X-linked Intellectual disability, AP1S2-related | XL | General Population | <1 in 50,000 | 99% | 1 in 4,999,901 | <1 in 10 million | ||||||||||||||||||
82 | AP3B1 | Hermansky-Pudlak syndrome 2 | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
83 | AP3D1 | Hermansky-Pudlak syndrome 10 | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
84 | APOPT1 | Mitochondrial complex IV deficiency | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
85 | AQP2 | Nephrogenic diabetes insipidus | AR | General Population | <1 in 500 | 95% | 1 in 9,981 | <1 in 10 million | ||||||||||||||||||
86 | Finnish Population | 1 in 169 | 95% | 1 in 3,361 | 1 in 2,272,036 | |||||||||||||||||||||
87 | AR | Androgen insensitivity syndrome | XL | General Population | 1 in 14,286 | 98% | 1 in 714,251 | 1 in 1,428,571 | ||||||||||||||||||
88 | ARG1 | Arginase deficiency | AR | General Population | 1 in 296 | 98% | 1 in 14,751 | <1 in 10 million | ||||||||||||||||||
89 | ARL13B | Joubert syndrome, ARL13B-related | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
90 | ARSA | Metachromatic leukodystrophy | AR | General Population | 1 in 100 | 99% | 1 in 9,901 | 1 in 3,960,400 | ||||||||||||||||||
91 | Caucasian / European Population | 1 in 78 | 99% | 1 in 7,701 | 1 in 2,402,712 | |||||||||||||||||||||
92 | Yemenite Jewish Population | 1 in 75 | 99% | 1 in 7,401 | 1 in 2,220,300 | |||||||||||||||||||||
93 | ARSB | Mucopolysaccharidosis type VI (Maroteaux- | AR | General Population | 1 in 250 | 98% | 1 in 12,451 | <1 in 10 million | ||||||||||||||||||
94 | Lamy syndrome) | Western Australian Population | 1 in 283 | 98% | 1 in 14,101 | <1 in 10 million | ||||||||||||||||||||
95 | ARSE | Chondrodysplasia punctata type 1, X-linked | XL | General Population | 1 in 250,000 | 98% | 1 in 12,499,951 | <1 in 10 million | ||||||||||||||||||
96 | ARX | X-linked intellectual disability, ARX-related | XL | General Population | <1 in 50,000 | 99% | 1 in 4,999,901 | <1 in 10 million | ||||||||||||||||||
97 | ASL | Argininosuccinate lyase deficiency | AR | General Population | 1 in 132 | 90% | 1 in 1,311 | 1 in 692,208 | ||||||||||||||||||
98 | ASNS | Asparagine synthetase deficiency | AR | General Population | <1 in 500 | 99% | 1 in 49,901 | <1 in 10 million | ||||||||||||||||||
99 | Iranian Jewish Population | 1 in 80 | 99% | 1 in 7,901 | 1 in 2,528,320 | |||||||||||||||||||||
100 | ASPA | Canavan disease | AR | General Population | 1 in 300 | 97% | 1 in 9,968 | <1 in 10 million |